KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Resmed (RMD) EPS (Weighted Average and Diluted) (2016 - 2025)

Resmed (RMD) has disclosed EPS (Weighted Average and Diluted) for 17 consecutive years, with $2.68 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) rose 14.53% year-over-year to $2.68, compared with a TTM value of $10.11 through Dec 2025, up 19.36%, and an annual FY2025 reading of $9.51, up 37.43% over the prior year.
  • EPS (Weighted Average and Diluted) was $2.68 for Q4 2025 at Resmed, up from $2.37 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $2.68 in Q4 2025 and bottomed at -$0.54 in Q1 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is $1.68, with a median of $1.54 recorded in 2023.
  • The sharpest move saw EPS (Weighted Average and Diluted) plummeted 148.21% in 2021, then skyrocketed 324.07% in 2022.
  • Year by year, EPS (Weighted Average and Diluted) stood at $1.37 in 2021, then increased by 11.68% to $1.53 in 2022, then fell by 7.19% to $1.42 in 2023, then soared by 64.79% to $2.34 in 2024, then grew by 14.53% to $2.68 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for RMD at $2.68 in Q4 2025, $2.37 in Q3 2025, and $2.58 in Q2 2025.